In particular, treatment with risperidone, as the least atypical antipsychotic, led to an increase in pro-inflammatory IFN-α2, IL-1β, and IL-7 in schizophrenia patients with metabolic syndrome and was ineffective in lowering pro-inflammatory cytokines in patients without it. This evidence concerns the gene IFNA2 and metabolic syndrome.